Stockreport

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite a [Read more]